Analysts Set Flexion Therapeutics Inc (NASDAQ:FLXN) PT at $22.15

Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) have earned a consensus rating of “Buy” from the sixteen analysts that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $22.15.

Several analysts recently issued reports on FLXN shares. ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, August 24th. Zacks Investment Research cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 4th. Northland Securities initiated coverage on shares of Flexion Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer initiated coverage on shares of Flexion Therapeutics in a report on Thursday, July 30th. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, Guggenheim initiated coverage on shares of Flexion Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $20.00 price objective for the company.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FLXN. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Flexion Therapeutics in the first quarter worth $113,000. New York State Common Retirement Fund grew its stake in shares of Flexion Therapeutics by 163.8% in the first quarter. New York State Common Retirement Fund now owns 75,715 shares of the specialty pharmaceutical company’s stock worth $596,000 after acquiring an additional 47,015 shares during the last quarter. Wasatch Advisors Inc. grew its stake in shares of Flexion Therapeutics by 6.8% in the first quarter. Wasatch Advisors Inc. now owns 2,315,642 shares of the specialty pharmaceutical company’s stock worth $18,224,000 after acquiring an additional 146,785 shares during the last quarter. Aigen Investment Management LP grew its stake in shares of Flexion Therapeutics by 58.0% in the first quarter. Aigen Investment Management LP now owns 21,169 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 7,774 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in shares of Flexion Therapeutics by 7.2% in the first quarter. Commonwealth Equity Services LLC now owns 61,300 shares of the specialty pharmaceutical company’s stock worth $482,000 after acquiring an additional 4,130 shares during the last quarter. 90.91% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ FLXN opened at $12.45 on Friday. The company has a debt-to-equity ratio of 12.77, a current ratio of 6.60 and a quick ratio of 6.08. The stock has a market capitalization of $613.76 million, a PE ratio of -3.47 and a beta of 2.02. Flexion Therapeutics has a 1 year low of $5.01 and a 1 year high of $22.98. The business’s 50-day moving average is $12.30 and its 200 day moving average is $11.21.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Wednesday, August 5th. The specialty pharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.06). The business had revenue of $15.45 million during the quarter, compared to the consensus estimate of $15.46 million. Flexion Therapeutics had a negative return on equity of 592.50% and a negative net margin of 174.25%. As a group, equities research analysts anticipate that Flexion Therapeutics will post -2.72 earnings per share for the current year.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Article: How to Invest in an Index Fund

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.